ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer
Public ClinicalTrials.gov record NCT00325351. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/2 Study of ZK-Epothilone (ZK-Epo; ZK-219477) in Combination With Carboplatin in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) given with carboplatin in patients with recurrent ovarian cancer, who previously have had a good response with cisplatin or carboplatin, is safe and helps to decrease or stop tumor growth.
Study identification
- NCT ID
- NCT00325351
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 45 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 24, 2006 (Actual)
- Primary completion
- Jul 8, 2008 (Actual)
- Completion
- Mar 25, 2009 (Actual)
- Last update posted
- Apr 8, 2021
2006 – 2009
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Tucson | Arizona | 85724 | — |
| Not listed | Little Rock | Arkansas | 72205 | — |
| Not listed | Bakersfield | California | 93309 | — |
| Not listed | La Jolla | California | 92093 | — |
| Not listed | San Diego | California | 92121 | — |
| Not listed | Savannah | Georgia | 31404 | — |
| Not listed | South Bend | Indiana | 46617 | — |
| Not listed | Baltimore | Maryland | 21204 | — |
| Not listed | Albuquerque | New Mexico | 87131 | — |
| Not listed | Winston-Salem | North Carolina | 27157 | — |
| Not listed | Cleveland | Ohio | 44109 | — |
| Not listed | Oklahoma City | Oklahoma | 73104 | — |
| Not listed | Knoxville | Tennessee | 37920 | — |
| Not listed | Roanoke | Virginia | 24014 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00325351, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 8, 2021 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00325351 live on ClinicalTrials.gov.